Histogenics (HSGX) Competitors

Histogenics (NASDAQ:HSGX) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Does the media favor HSGX or INGN?

In the previous week, Inogen had 13 more articles in the media than Histogenics. MarketBeat recorded 13 mentions for Inogen and 0 mentions for Histogenics. Inogen's average media sentiment score of 0.43 beat Histogenics' score of 0.00 indicating that Inogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Histogenics	Neutral
Inogen	Neutral

Is HSGX or INGN more profitable?

Histogenics has a net margin of 0.00% compared to Inogen's net margin of -15.89%. Inogen's return on equity of -27.38% beat Histogenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Histogenics	N/A	-34.96%	18.40%
Inogen	-15.89%	-27.38%	-16.77%

Do analysts prefer HSGX or INGN?

Inogen has a consensus target price of $7.00, suggesting a potential downside of 40.12%. Given Inogen's stronger consensus rating and higher probable upside, analysts clearly believe Inogen is more favorable than Histogenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Histogenics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Inogen	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Does the MarketBeat Community believe in HSGX or INGN?

Inogen received 29 more outperform votes than Histogenics when rated by MarketBeat users. However, 71.66% of users gave Histogenics an outperform vote while only 69.16% of users gave Inogen an outperform vote.

Company	Underperform	Outperform
Histogenics	Outperform Votes 359 71.66%	Underperform Votes 142 28.34%
Inogen	Outperform Votes 388 69.16%	Underperform Votes 173 30.84%

Which has higher valuation and earnings, HSGX or INGN?

Histogenics has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Histogenics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Histogenics	N/A	N/A	-$8.64M	-$0.79	-0.97
Inogen	$315.66M	0.88	-$102.45M	-$2.25	-5.20

Which has more risk & volatility, HSGX or INGN?

Histogenics has a beta of 3.1, suggesting that its stock price is 210% more volatile than the S&P 500. Comparatively, Inogen has a beta of 1.02, suggesting that its stock price is 2% more volatile than the S&P 500.

Do institutionals and insiders hold more shares of HSGX or INGN?

40.4% of Histogenics shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 19.7% of Histogenics shares are held by insiders. Comparatively, 1.0% of Inogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Inogen beats Histogenics on 9 of the 17 factors compared between the two stocks.